title: Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies.
abstract: Approaches in disruption of MDM2-p53 interactions have now emerged as an important therapeutic strategy in resurrecting wild type p53 functional status. The present study highlights virtual screening strategies in identification of high affinity small molecule non-peptidic inhibitors. Nutlin3A and RG7112 belonging to compound class of Cis-imidazoline, MI219 of Spiro-oxindole class and Benzodiazepine derived TDP 665759 served as query small molecules for similarity search with a threshold of 95%. The query molecules and the similar molecules corresponding to each query were docked at the transactivation binding cleft of MDM2 protein. Aided by MolDock algorithm, high affinity compound against MDM2 was retrieved. Patch Dock supervised Protein-Protein interactions were established between MDM2 and ligand (query and similar) bound and free states of p53. Compounds with PubCid 68870345, 77819398, 71132874, and 11952782 respectively structurally similar to Nutlin3A, RG7112, Mi219 and TDP 665759 demonstrated higher affinity to MDM2 in comparison to their parent compounds. Evident from the protein-protein interaction studies, all the similar compounds except for 77819398 (similar to RG 7112) showed appreciable inhibitory potential. Of particular relevance, compound 68870345 akin to Nutlin 3A had highest inhibitory potential that respectively showed 1.3, 1.2, 1.16 and 1.26 folds higher inhibitory potential than Nutilin 3A, MI 219, RG 7112 and TDP 1665759. Compound 68870345 was further mapped for structure based pharamacophoric features. In the study, we report Cis-imidazoline derivative compound; Pubcid: 68870345 to have highest inhibitory potential in blocking MDM2-p53 interactions hitherto discovered.
authors.affiliation: Institute of Genetics and Hospital for Genetic Diseases, Osmania University, India E-mail : anuraj@eminentbio.com.
authors.forename: Srinivas
authors.initials: S
authors.lastname: Bandaru
authors.forename: Deepika
authors.initials: D
authors.lastname: Ponnala
authors.forename: Chandana
authors.initials: C
authors.lastname: Lakkaraju
authors.forename: Chaitanya Kumar
authors.initials: CK
authors.lastname: Bhukya
authors.forename: Uzma
authors.initials: U
authors.lastname: Shaheen
authors.forename: Anuraj
authors.initials: A
authors.lastname: Nayarisseri
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D003198:Computer Simulation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D048288:Imidazolines / Q000494:pharmacology; D062105:Molecular Docking Simulation; D010879:Piperazines / Q000494:pharmacology; D011485:Protein Binding; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D054852:Small Molecule Libraries / Q000494:pharmacology*; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D048288:Imidazolines; D010879:Piperazines; C579783:RG7112; D054852:Small Molecule Libraries; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C482205:nutlin 3; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2